CRXT
Income statement / Annual
Last year (2021), Clarus Therapeutics Holdings, Inc.'s total revenue was $13.96 M,
and the percentage change from the previous year is not available.
In 2021, Clarus Therapeutics Holdings, Inc.'s net income was -$56.51 M.
See Clarus Therapeutics Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$13.96 M
|
$0.00
|
| Cost of Revenue |
$2.72 M |
$0.00 |
| Gross Profit |
$11.24 M |
$0.00 |
| Gross Profit Ratio |
0.81 |
0 |
| Research and Development
Expenses |
$3.63 M
|
$0.00
|
| General & Administrative
Expenses |
$16.66 M
|
$2.98 M
|
| Selling & Marketing
Expenses |
$30.68 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$47.34 M
|
$2.98 M
|
| Other Expenses |
$0.00 |
$0.00 |
| Operating Expenses |
$50.97 M |
$2.98 M |
| Cost And Expenses |
$53.69 M |
$2.98 M |
| Interest Income |
$2,000.00 |
$0.00 |
| Interest Expense |
$15.90 M |
$0.00 |
| Depreciation &
Amortization |
$25,000.00
|
$206,297.00
|
| EBITDA |
-$39.73 M
|
-$47.18 M
|
| EBITDA Ratio |
-2.85 |
0 |
| Operating Income Ratio
|
-1.77
|
0
|
| Total Other
Income/Expenses Net |
-$15.90 M
|
$0.00
|
| Income Before Tax |
-$40.62 M |
$0.00 |
| Income Before Tax Ratio
|
-2.91
|
0
|
| Income Tax Expense |
$15.90 M |
$0.00 |
| Net Income |
-$56.51 M |
$0.00 |
| Net Income Ratio |
-4.05 |
0 |
| EPS |
-2.35 |
0 |
| EPS Diluted |
-2.35 |
0 |
| Weighted Average Shares
Out |
$24.03 M
|
$21.73 M
|
| Weighted Average Shares
Out Diluted |
$24.03 M
|
$21.73 M
|
| Link |
|
|
